Mount Sinai researchers have found strong evidence that before the first symptoms of Crohn’s disease and ulcerative colitis occur, there’s a preclinical phase in which immune and inflammatory pathways are already altered. By targeting and treating the early pathogenic events that promote IBD development, they believe, disease onset could be prevented or impeded.